PARP1 and cancer: Molecular-targeting based therapy in the CRPC setting by PARP inhibitors includes olaparib, a small potent molecule inhibitor of PARP1 and PARP2 enzymes [14], which causes an accumulation of DNA damage in rapidly dividing cancer cells.